Clinical trial · Interventional
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
Phase II Study of Cladribine, High-dose Cytarabine and Idarubicin in Patients With Relapsed Acute Myeloid Leukemia
NCT00126321CI-TRIAL-00003088unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Myelocytic, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cladribine | Drug | Cladribine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Toxicity according to National Cancer Institute/Common Toxicity Criteria (NCI/CTC), especially the rate of severe infections and the death rate
- timeFrame
- continuous
- measure
- Rate of complete remission
Secondary outcomes (4)
- measure
- Remission duration
- measure
- Overall survival
- measure
- Influence of cytogenetic aberrations on remission rate, duration of remission and overall survival
- measure
- Course of CD3/CD4+ subpopulation after therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with relapsed AML with a remission duration of at least 6 months after first complete remission (CR) or of at least 3 months after second (or higher) CR * Age \>= 18 years * Life expectancy of at least three months (without consideration of AML and complications) * Eastern Cooperative Oncology Group (ECOG) 0-2 (without consideration of AML and complications) * Written informed consent Exclusion Criteria: * Prior therapy of AML with cladribine * Severe, uncontrolled infection at time of inclusion (enrollment is possible after control of infection) * Cardiac insufficiency grade III or IV New York Heart Association (NYHA) * Severe renal insufficiency with a clearance of \< 30 ml/min (if not due to AML) * Severe hepatic insufficiency with bilirubin \> 3 mg/dl or AST \> 200 U/l (if not due to AML) * Other severe organ impairment grade III or IV World Health Organization (WHO) (if not due to AML or, in the opinion of the investigator, may not interfere with the procedures in the study) * HIV infection * Intolerance to study drugs * Pregnant or breast-feeding women * Any other malignant disease which will probably affect the course of AML
References
Publications (0)
Data not yet available
No reference posted for this study.